point
care
poc
devic
one
use
outsid
central
laboratori
environ
gener
near
site
patientcli
point
care
test
poct
vari
test
perform
physician
fi
ce
lab
satellit
stat
lab
test
perform
tabletop
instrument
clinic
area
test
perform
handheld
instrument
bedsid
peripher
lab
set
poct
may
perform
train
laboratori
staff
clinic
bedsid
poct
frequent
perform
staff
lack
special
laboratori
train
whose
primari
job
someth
lab
test
industri
world
poct
commonli
use
provid
result
within
medic
decisionmak
infect
control
intervent
action
timefram
order
acceler
streamlin
care
timefram
differ
depend
natur
serious
infecti
process
purpos
discuss
maximum
h
may
reason
upper
limit
sampl
collect
result
deliveri
within
scope
poc
test
clinic
situat
long
clinic
decis
must
made
without
test
result
guidanc
poct
also
use
especi
resourcelimit
set
provid
laboratori
result
unavail
way
may
provid
simpl
test
system
use
stabl
reagent
provid
rapid
result
novel
system
remot
test
eg
view
malaria
smear
via
mobil
phone
also
come
use
might
fi
oper
de
fi
nition
poct
sever
reason
develop
poc
test
infecti
diseas
includ
need
quickli
provid
highli
target
therapi
current
algorithm
serious
ill
patient
depend
empir
treatment
base
like
pathogen
given
clinic
present
howev
method
involv
broadspectrum
therapi
cover
like
conting
know
exact
identi
fi
cation
pathogen
allow
focus
therapeut
decis
molecular
method
also
detect
import
resist
factor
pathogen
therapeut
decis
made
speci
fi
calli
treat
pathogen
limit
develop
resist
organ
poct
infecti
diseas
molecular
assay
may
develop
detect
speci
fi
c
infect
rapid
respons
desir
exampl
includ
common
outpati
infect
group
streptococc
pharyng
immedi
diagnosi
save
followup
effort
chlamydia
gonorrhea
rapid
result
may
allow
immedi
treatment
patient
might
otherwis
lost
followup
potenti
clinic
public
health
bene
fi
ts
class
test
anoth
potenti
object
poct
recogn
quickli
patient
requir
infect
control
precaut
admit
healthcar
institut
prevent
spread
agent
patient
caregiv
poc
assay
meant
surveil
case
intervent
taken
break
transmiss
rout
prevent
develop
infect
increasingli
healthcar
institut
ask
becom
costeffect
rapid
applic
infect
control
activ
shown
effect
potenti
poct
impact
infectioncontrol
particularli
signi
fi
cant
longterm
care
facil
health
care
set
without
onsit
laboratori
platform
employ
molecular
technolog
simpl
enough
potenti
poc
use
begin
come
market
molecular
test
yet
achiev
clia
waiv
statu
although
develop
fda
submiss
poc
molecular
test
still
physician
fi
ce
lab
satellit
lab
test
rather
true
bedsid
method
sever
compar
simpl
rapid
molecular
method
though
avail
increasingli
use
wide
use
molecular
test
patient
poc
site
realtim
pcr
rtpcr
assay
detect
nasal
colon
methicillinresist
staphylococcu
aureu
mrsa
colon
patient
place
contact
isol
decolon
protocol
initi
appropri
surgic
prophylaxi
use
use
assay
within
unit
state
veteran
administr
hospit
one
factor
credit
lower
healthcareassoci
mrsa
infect
sinc
univers
screen
addit
infect
control
intervent
implement
select
nosocomi
infect
due
clostridium
dif
fi
cile
vancomycinresist
enterococci
vre
also
decreas
two
report
use
surveil
mrsa
illustr
effect
intervent
rapid
result
avail
within
hour
patient
admiss
northshor
hospit
system
show
decreas
hospitalassoci
mrsa
diseas
studi
period
contrast
anoth
healthcar
institut
use
slower
method
mrsa
nasal
surveil
result
avail
day
later
result
disappoint
molecular
poc
tool
virtual
method
possibl
achiev
effect
infect
control
addit
assay
detect
mrsa
methicillinsuscept
staphylococci
patient
skin
soft
tissu
wound
site
nare
also
avail
test
fece
presenc
toxigen
c
dif
fi
cile
anoth
use
rapid
molecular
technolog
today
rtpcr
platform
loopmedi
isotherm
ampli
fi
cation
lamp
platform
fdaclear
employ
differ
target
lamp
assay
seek
genet
locu
tcda
gene
c
dif
fi
cile
wherea
pcr
assay
either
identifi
portion
toxin
b
gene
tcdb
second
fdaclear
assay
presumpt
identi
fi
es
epidem
hypervirul
strain
detect
binari
toxin
sequenc
delet
toxin
regulatori
gene
addit
tcdb
gene
rtpcr
platform
fdaclear
detect
fl
uenza
b
fl
uenza
novel
respiratori
secret
modi
fi
cation
previou
test
avail
limit
time
fl
uenza
outbreak
addit
selfcontain
pcr
technolog
use
packet
reagent
plastic
pouch
also
fdaclear
detect
respiratori
virus
anoth
rapid
molecular
test
fdaclear
multiplex
detect
respiratori
virus
includ
adenoviru
coronaviru
strain
fl
uenza
strain
human
metapneumoviru
parain
fl
uenza
viru
type
rsv
rhinoenteroviru
timetoresult
h
use
novel
multiplex
pcr
array
detect
format
although
pcr
method
viru
detect
identi
fi
cation
respiratori
secret
avail
show
excel
sensit
speci
fi
citi
candid
poc
test
due
complex
long
perform
time
format
lead
inef
fi
cienci
perform
nonbatch
stat
test
fdaclear
rtpcr
assay
use
detect
gastrointestin
colon
vre
use
rectal
swab
us
version
test
develop
detect
vana
gene
vanb
vre
uncommon
unit
state
today
vanbcontain
nonenterococci
enterococci
fece
commonli
use
fdaclear
pcr
platform
anoth
enterococc
assay
detect
vana
vanb
speci
fi
citi
vanb
marker
poor
format
optim
poc
platform
describ
vre
staphylococci
fdaclear
direct
detect
group
b
streptococci
gb
vaginalrect
swab
assay
use
time
deliveri
test
women
never
receiv
antenat
surveil
cultur
gb
women
test
neg
surveil
cultur
whose
colon
statu
may
chang
time
cultur
present
labor
addit
platform
fdaclear
test
presenc
enteroviru
cerebrospin
fl
uid
unlik
test
avail
platform
csf
enteroviru
assay
design
high
complex
due
need
test
person
pipett
speci
fi
c
l
volum
csf
cartridg
lightcycl
rtpcr
platform
use
develop
test
herp
simplex
varicella
zoster
viru
cerebrospin
fl
uid
could
consid
borderlin
poc
test
order
stat
highli
train
laboratori
scientist
could
theoret
perform
test
report
result
within
h
timefram
unlik
howev
case
sever
diseas
clinician
treat
patient
would
will
wait
long
treat
base
clinic
present
csf
cell
count
separ
microbiolog
laboratori
result
direct
dna
hybrid
assay
identi
fi
cation
gardnerella
vaginali
marker
bacteri
vaginosi
candida
albican
trichomona
vaginali
use
larg
physician
fi
ce
refer
laboratori
mani
year
test
run
batch
fewer
sampl
result
avail
within
h
countri
unit
state
rtpcr
method
use
detect
mycobacterium
tuberculosi
rifampinresist
tuberculosi
use
heminest
pcr
protocol
use
fi
molecular
beacon
bind
differ
region
ribosom
polymeras
b
gene
mutat
confer
rifampin
resist
found
fi
region
bind
speci
fi
calli
color
fl
uoresc
beacon
organ
wildtyp
tuberculosi
one
region
fail
bind
speci
fi
c
beacon
least
two
region
present
tuberculosi
strain
report
resist
test
use
unprocess
respiratori
tract
secret
patient
locat
result
avail
within
h
studi
shown
even
unskil
worker
achiev
high
level
accuraci
assay
achiev
endors
world
health
organ
broadli
dissemin
throughout
resourcepoor
world
overlook
sever
poc
diagnost
detect
agent
bioterror
anthrax
yersinia
pesti
francisella
tularensi
easili
weapon
agent
test
develop
fi
eld
test
detect
environ
eg
powder
patient
sever
attract
target
poc
infecti
diseas
diagnost
exist
includ
diagnosi
bacteremia
fungemia
current
culturebas
technolog
requir
incub
least
hour
fi
rst
indic
posit
result
organ
rapidli
identi
fi
ed
use
molecular
method
howev
appropri
therapi
within
fi
rst
hour
often
make
differ
sever
morbid
death
recoveri
number
circul
bacteria
yeast
bloodstream
septicem
patient
low
volum
blood
necessari
detect
small
number
organ
limit
applic
molecular
method
effect
frontend
concentr
system
develop
diagnosi
extrem
sever
infect
approach
poc
test
mening
enceph
potenti
sever
infect
bene
fi
earli
diagnosi
patient
appropri
manag
limit
number
common
pathogen
associ
cn
infect
make
develop
test
feasibl
addit
agent
rapid
simpl
molecular
test
need
includ
neisseria
meningitidi
streptococcu
pneumonia
gb
listeria
haemophilu
fl
uenza
herp
simplex
varicella
zoster
viru
test
diagnosi
manag
diseas
seen
outpati
particularli
hardtomanag
popul
poc
test
std
respiratori
virus
group
streptococci
hiv
hcv
viral
load
potenti
streamlin
care
condit
allow
samevisit
manag
decreas
effort
followup
potenti
public
health
impact
patient
contact
deliv
result
mani
clinician
infect
preventionist
concern
rise
incid
multidrugresist
gramneg
rod
metallobetalactamas
carbapenemas
cephalosporinas
etc
pose
risk
patient
problem
infect
control
rapid
molecular
test
detect
major
determin
resist
regardless
organ
carri
would
desir
rapid
poc
test
sever
pathogen
detect
patient
sampl
use
molecular
test
within
h
howev
formid
obstacl
move
molecular
diagnost
poc
set
includ
impract
perform
method
random
access
batch
mode
need
highli
train
individu
perform
test
must
locat
poc
inef
fi
cienci
individu
wait
time
test
request
need
space
instrument
suppli
physic
infrastructur
exist
poc
locat
delay
incur
addit
sampl
receiv
test
test
process
commenc
stop
middl
need
test
necessari
control
individu
sampl
rather
group
patient
sampl
need
addit
instrument
sampl
prepar
preampli
fi
cation
possibl
contamin
factor
consid
remain
current
technolog
includ
polymeras
chain
reaction
isotherm
loopmedi
ampli
fi
cation
direct
dna
hybrid
method
earlier
stage
develop
may
show
potenti
futur
molecular
method
brought
routin
poc
use
potenti
provid
perform
equival
laboratorybas
method
method
must
chosen
extrem
sensit
detect
small
number
organ
limit
sampl
volum
autom
miniatur
platform
desir
situat
number
infecti
diseas
exampl
tubercul
mening
paucibacillari
natur
cerebrospin
fl
uid
challeng
develop
effect
molecular
assay
molecular
method
poc
bring
new
challeng
administ
perform
poct
addit
usual
qa
qc
associ
poct
molecular
poct
requir
procedur
control
contamin
ampli
fi
ed
materi
patientderiv
materi
qc
stage
analyt
procedur
extract
ampli
fi
cation
detect
may
make
troubleshoot
challeng
phenomenon
inhibit
specimen
may
requir
oper
report
complex
result
posit
neg
poc
molecular
instrument
like
complex
current
system
glucos
test
system
may
initi
lack
sophist
poc
manag
tool
associ
tradit
poc
platform
molecular
diagnost
technolog
transform
diagnosi
infecti
diseas
current
emerg
clinic
need
increas
acuiti
inpati
care
expand
outpati
care
increasingli
mobil
popul
need
control
healthcareacquir
infect
novel
antibiot
resist
mechan
drive
molecular
microbiolog
poc
